Effect of the Biological Drug Etanercept on Tumor necrosis factor-α Levels in Psoriatic Patients
Psoriasis is a common, chronic, immune mediated disorder.The disease is arising as a result of dysregulated interactions of the innate and adaptive immune system in the context of skin epithelium and connective tissue. The biological drug Etanercept(ETN) approved for use in treated psoriasis. ETN is tumor necrosis factor- α (TNF-α) inhibitor. In this study, 48 psoriatic patients were taken before and after treatment who attended to the Dermatology and Venereology Department in Baghdad Teaching Hospital during the period from December 2016 to September 2017and 50 samples were used as healthy control group. The results showed that most psoriatic patients 52.08 % were within the second and third decades 20-35 year, and the majority of psoriatic patients were males 62.5% and the ratio of male to female is 1.67:1. Moreover, the results demonstrated that the males were more expected psoriasis compare with females. Blood samples were collected and TNF- α was estimated in sera of all subjects by using Enzyme Linked Immunosorbent Assay (ELISA). The TNF- α mean levels in psoriatic patients before treatment was 189.5±26.0 ng/ml, and after treatment was 223.6±41.1 ng/ml compar with the healthy control group 93.5±2.4 ng/ml. The results showed significant differences between the studied groups.